The mechanism behind down-regulation of KAI1 expression during cancer development is complex, mediated by transcription control, alternative splicing, and even post-translational remodeling (Tonoli and Barrett, 2005; Tsai et al., 2007; Lee et al., 2011). Here, CD82 is linked to cancer.